Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years

Rhea-AI Filing Summary

Daniel Mark James reported acquisition or exercise transactions in this Form 4 filing.

Atossa Therapeutics’ Chief Financial Officer Daniel Mark James received a grant of 63,000 restricted stock units of common stock. The award was granted at no cash cost to him and brings his reported direct holdings to 63,000 shares-equivalent.

The RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026, meaning the award is structured to retain and incentivize the CFO over multiple years.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Daniel Mark James

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	63,000	$0.00	--

Holdings After Transaction: Common Stock — 63,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 63,000 units Price per RSU: $0.0000 per unit Post-transaction holdings: 63,000 shares-equivalent +1 more

4 metrics

RSU grant size 63,000 units Restricted stock units granted to CFO Daniel Mark James

Price per RSU $0.0000 per unit Reported transaction price for granted RSUs

Post-transaction holdings 63,000 shares-equivalent Total direct holdings following RSU grant

Vesting schedule 3 equal annual installments On first three anniversaries of March 26, 2026

Key Terms

restricted stock units, RSUs, contingent right, vest

4 terms

restricted stock units financial

"Represents a grant of restricted stock units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vest financial

"The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniel Mark James

(Last) (First) (Middle)

C/O ATOSSA THERAPEUTICS, INC.

1448 NW MARKET STREET, SUITE 500

(Street)

SEATTLE WASHINGTON 98107

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ATOSSA THERAPEUTICS, INC. [ ATOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/26/2026		A		63,000(1)	A	$0	63,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026.

	/s/ Mark James Daniel	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Atossa Therapeutics (ATOS) report for its CFO?

Atossa Therapeutics reported that CFO Daniel Mark James received a grant of 63,000 restricted stock units. These RSUs represent rights to receive common shares over time, aligning his compensation with shareholder interests through equity rather than immediate cash.

How many Atossa (ATOS) shares are covered by the CFO’s new RSU grant?

The CFO’s award covers 63,000 restricted stock units, with each RSU corresponding to one share of Atossa common stock. When fully vested and settled, this grant would deliver 63,000 shares, assuming all vesting conditions are satisfied and no forfeitures occur.

What is the vesting schedule for the Atossa (ATOS) CFO’s 63,000 RSUs?

The 63,000 RSUs granted to Atossa’s CFO vest in three equal annual installments. Vesting occurs on the first three anniversaries of March 26, 2026, meaning the award becomes fully vested over a three-year period, contingent on continued service or other plan conditions.

Did the Atossa (ATOS) CFO pay cash for the 63,000 RSUs he received?

No cash payment was reported for the CFO’s RSU grant, which was recorded at a price per share of 0.0000. This indicates a compensation-related equity award rather than an open-market purchase of Atossa common stock by the executive.

How many Atossa (ATOS) shares does the CFO hold after this RSU grant?

Following the grant, the Form 4 shows the CFO with 63,000 shares-equivalent directly owned. This figure reflects the RSU award reported in the filing and represents his position as of the transaction date disclosed for the grant.

Is the Atossa (ATOS) CFO’s RSU grant a buy or a compensation award?

The transaction is classified as a grant or award acquisition, not an open-market buy. Code “A” and the zero purchase price indicate it is part of the CFO’s compensation package, delivering equity subject to the stated vesting schedule.